Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ZoomInfo raises FY24 adjusted EPS view to $1.00-$1.02 from 99c-$1.01
Consensus is $1.00. Adjusts FY24 revenue view to $1.255B-$1.27B from $1.26B-$1.28B, consensus $1.27B.
goooooooooooooooooooooood evening
Lyft reports Q1 GAAP EPS (8c), consensus 3c
Reports Q1 revenue $1.3B, consensus $1.16B. Rides of 188 million: were up 23% year-over-year, reflecting strong demand across use cases. Growth in early morning, commute and weekend evening trips was particularly strong, which is a continuation of the trends we saw in the back half of 2023. Active Riders of 21.9 million: were up 12% year-over-year, reflecting an improvement in rider retention along with an increase in new riders. "Lyft is off to a strong start in 2024. We are executing well and bringing much-needed innovation to the market. That's why drivers and riders are choosing Lyft more often," said CEO David Risher. "After a year in the driver's seat at Lyft I'm thrilled to see all the ways that our customer obsession drives profitable growth."
Reddit reports Q1 EPS ($8.19), consensus ($8.71)
Have a great afternoon all! Even you Ranger Fans...
$SMCI 14.7%
$AAPL 4.6%
$COIN 12.9%
$AMZN 7.6%
$SQ 11.7%
$DKNG 10.8%
$AMD 8.6%
$NVO 6.1%
$MCD 3.0%
$PYPL 9.1%
$LLY 5.2%
$SBUX 6.6%
$QCOM 7.9%
$CVNA 17.9%
$ETSY 11.3%
$FSLY 18.1%
$FSLR 9.0%
$MGM 6.3%
$CAR 16.2%?
$MOS 6.5%
$MET 4.4%
$ZG 12.9%
$PTON 21.0%
$W 14.9%
$CI 4.1%
?$REGN 5.0%
$INMD 11.7%
$SWK 7.3%
$NET 13.6%
$BKNG 5.7%
$FTNT 10.4$
$EXPE 9.6%
?$AMGN 5.0%
$ILMN 8.3%
$GDDY 7.6%
$TRUP 21.0%
$WW 21.5%
$TNDM 16.4%
$FUBO 23.1%
$LNG 4.4%
$XPO 12.1%
$LMND 16.4%
$ROOT 30.2%
$MDLZ 3.4%
$SYK 5.7%
$CLX 5.4%
$LC 13.3%
$PRU 5.0%
$INVH 4.2%
$PFE 4.6%?
$CVS 5.3%
?$MA 4.2%
?$WING 11.7%
$KHC 4.1%
$MAR 5.0%
$MMM 5.7%
$KO 2.2%
$CCJ 7.6%
$ETN 7.1%
$GLW 4.8%
$EL 9.9%
$GRMN 5.7%
$YUM 4.4%
$DD 5.4%
Datadog price target lowered to $140 from $155 at BMO Capital
BMO Capital lowered the firm's price target on Datadog to $140 from $155 and keeps an Outperform rating on the shares. Against high expectations, the company reported "solid" quarterly results, though there were a few "disappointing" metrics, the analyst tells investors in a research note. The firm said it continues to rate the name Outperform based on its view that Datadog's expanding portfolio can sustain durable growth.
TRUP HoD
Reddit Inc options imply 12.7% move in share price post-earnings
Pre-earnings options volume in Reddit Inc is normal with calls leading puts 5:4. Implied volatility suggests the market is anticipating a move near 12.7%, or $6.20, after results are released
HSBC upgrades Cognex to Buy on demand turnaround
HSBC upgraded Cognex to Buy from Hold with a price target of $52, up from $40. After six quarters of revenue declines year-over-year, the company's Q1 recorded growth of 5%, the analyst tells investors in a research note. The firm sees more upside in the shares given the better than expected logistics and semiconductor outlook. Logistics demand is improving while Cognex's semi business is stronger from artificial intelligence-driven high bandwidth memory demand and Moritex, contends HSBC. It believes the demand turnaround and faster margin recovery will drive re-rating of Cognex shares.
Canopy Growth call volume above normal and directionally bullish
Bullish option flow detected in Canopy Growth with 23,541 calls trading, 1.2x expected, and implied vol increasing over 3 points to 152.69%. May-24 11 calls and May-24 11 puts are the most active options, with total volume in those strikes near 6,100 contracts. The Put/Call Ratio is 0.33. Earnings are expected on May 30th.
Fed's Kashkari questioned the degree of policy restrictiveness
Fed's Kashkari questioned the degree of policy restrictiveness in an essay published on the Minneapolis Fed website. He is a nonvoter who has been leaning to the hawkish side. The disinflation process seen in late 2023 seems to have stalled out in Q1 and wondered if that process is still underway. He suggested the "resilience" in the housing market to the higher rates "raises questions about whether policymakers and the market are misperceiving neutral, at lease in the near term. He also indicated that he raised his forecast for the long-run neutral rate to 2.5% from 2.0% (it was lifted to 2.6% in the March dot plot, from 2.5% in December). Uncertainty over the neutral rate creates a "challenge" for the Fed, and he added they "must set policy based on where neutral is in the short run." He concluded that the Fed has more work to do to achieve the dual mandate goals. He will be speaking later today in a fireside chat.
Morning Watch List : https://www.optionmillionaires.com/may-7th-2024-watch-list/
Gooooooooooood morning
Ligand Pharmaceuticals, Agenus in $100M royalty financing agreement
Ligand Pharmaceuticals Incorporated (LGND) and Agenus (AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that the companies have entered into a royalty financing agreement to support Agenus' key development initiatives in the ongoing BOT/BAL clinical development program, including its planned confirmatory Phase 3 trial in its lead indication of patients with metastatic, relapsed/refractory colorectal cancer not microsatellite instability-high or deficient mismatch repair (dMMR), who are without active liver metastases , along with other launch readiness activities. Under the terms of the agreement, Ligand will pay $75 million to Agenus at closing. In addition, Ligand has the option to invest an additional $25 million on the same terms on a pro rata basis. In return for the initial $75M payment, Ligand will receive 18.75% of the future royalties and 31.875% of the future milestone payments related to six of Agenus' clinical-stage partnered oncology programs, including BMS-986442 , AGEN2373 , INCAGN2385 and INCAGN2390 related to these six programs has the potential to exceed $400 million, with royalties in the low single digits. In addition, Ligand will also receive a 2.625% royalty on future global net sales generated by BOT/BAL. The royalties and milestone payments owed to Ligand could be adjusted up or down based upon pre-determined future events and achievements of certain milestones.
ivvd
vyd announced its intention to submit an emergency use authorization, EUA, application to the U.S. Food and Drug Administration, FDA, for pemivibart for the treatment of mild to moderate symptomatic COVID-19 in certain immunocompromised people utilizing a rapid immunobridging pathway. This immunobridging pathway leverages a similar approach Invivyd used to achieve its current EUA for PEMGARDA for pre-exposure prophylaxis of COVID-19 in certain immunocompromised people and was aligned in principle with the FDA. The immunobridging pathway for COVID-19 treatment is enabled by data from the Phase 2/3 clinical trial of adintrevimab, the prototype monoclonal antibody, for the treatment of COVID-191 and data from the ongoing CANOPY Phase 3 clinical trial of pemivibart for PrEP of COVID-19. The potential COVID-19 treatment EUA request would focus on the critical treatment needs of people in the U.S. who have moderate-to-severe immune compromise and for whom alternative COVID-19 treatment options are not clinically appropriate or accessible. Subsequent to the anticipated submission of an EUA request, Invivyd plans to initiate a compact clinical trial focused on confirmatory safety, pharmacokinetics, and clinical virology
Let Loose
It's showtime. The second-biggest U.S. company by market cap will be holding a "different kind of Apple Event" today, which is somewhat unusual timing given that it's only a month before Apple's (AAPL) annual Worldwide Developers Conference (WWDC). The Let Loose event promises to "draft up something special for you" and there is already much speculation before kickoff at 10 AM ET. Tune in at Apple Events, Apple TV, Apple Podcasts, or on YouTube Live.
iRumors: The event is likely to center around iPads and related accessories, such as the new generation of the iPad Pro with an OLED display. More importantly, it will be the first device powered by the new M4 chip, making it more powerful than the latest Mac and giving it the possibility of new AI capabilities. The biggest iPad Air on record might also be in store, with a 12.9-inch version that could make for a good alternative to the Pro, albeit with less power. There's also talk of slimmer bezels and camera repositioning, as well as other new hardware that might finally see the light of day, like upgrades to the Magic Keyboard and Apple Pencil.
Revenue in the category has been stalling lately, with no new iPad releases since 2022. That'll mean a lot is riding on the event for Apple, especially after a recent set of earnings that showed some sales weakness in several categories. However, Berkshire Hathaway's Warren Buffett is still calling for Apple (AAPL) to be his largest investment after the iPhone maker added a record $110B to its buyback program and raised its quarterly dividend by 4%.
More news: Apple is working on a "chip designed to run artificial intelligence software in data center servers," according to the Wall Street Journal. The project, which is internally code-named Project ACDC (Apple Chips in Data Center), is being coordinated with partner Taiwan Semiconductor Manufacturing (TSM) and could give the company a much-needed edge in the AI race. The latest effort is aimed at running AI models, rather than training them, and would build on other recent silicon success stories at Apple like custom in-house chips made for its devices. (3 comments)
Psychedelic therapy
An FDA advisory committee has been scheduled to meet next month to review data for the first-ever MDMA-assisted therapy for adults with post-traumatic stress disorder. This will be the first such review of a potential new PTSD treatment in 25 years, according to the therapy's manufacturer Lykos Therapeutics. MDMA - a party drug commonly known as ecstasy or molly - has not been approved by any regulator. A positive recommendation by the panel could bode well for other companies evaluating MDMA-assisted therapies such as Compass Pathways (CMPS) and Awakn Life Sciences (OTCQB:AWKNF). (1 comment)
Yen intervention
The Japanese government may have to intervene to support the yen (USD:JPY) in case of irregular, speculation-driven forex moves, said top currency official Masato Kanda. Many suspect Tokyo intervened twice last week, spending over JPY 9T ($58.3B) to support the currency, but the U.S. expects these interventions "to be rare and consultation to take place," Treasury Secretary Janet Yellen declared. The Bank of Japan is trying to avoid raising ultra-low interest rates through currency intervention, per SA analyst Harrison Schwartz, which "is akin to putting a band-aid on a wound that requires a tourniquet."
Another delay
Boeing (BA) can't seem to catch a break. Its first crewed Starliner mission launch was delayed once again because of a faulty oxygen relief valve on the Atlas V rocket, with plans to reattempt the launch on Friday. "We are just not willing to take any chances with what is our most precious payload," said Dillon Rice, engineer at United Launch Alliance, which is owned by Boeing and Lockheed Martin (LMT). The Starliner mission has been on hold for years, plagued by issues ranging from software coding to stuck valves. Meanwhile, Boeing is facing another regulatory probe, this time into its 787 Dreamliner inspections. (5 comments)
Today's Markets
In Asia, Japan +1.6%. Hong Kong -0.5%. China +0.2%. India -0.5%.
In Europe, at midday, London +1%. Paris +0.3%. Frankfurt +0.6%.
Futures at 7:00, Dow +0.2%. S&P +0.1%. Nasdaq -0.1%. Crude -0.4% to $78.20. Gold -0.3% at $2,323.50. Bitcoin -0.2% to $64,115.
Ten-year Treasury Yield -3 bps to 4.47%.
Today's Economic Calendar
11:30 Fed's Kashkari Speech
1:00 PM Results of $58B, 3-Year Note Auction
3:00 PM Consumer Credit
Companies reporting earnings today »
What else is happening...
WSB survey results: Space investment is way above the clouds.
Reddit (RDDT) to report first quarterly results as public company.
Disney (DIS), Comcast (CMCSA) turn to third firm to value Hulu.
Palantir (PLTR) tumbles despite raised guidance, earnings beat.
3 reasons why investors should stay in the market - BlackRock.
Robinhood's (HOOD) crypto division gets 'Wells notice' from SEC.
Crude rises on renewed Middle East tensions, Saudi price hikes.
Big Oil bemoans 'conflicting' rules on U.S. clean energy subsidies.
Spirit's (SAVE) losses accelerate on aircraft issues, competition.
Microsoft's (MSFT) new AI model said to rival Google and OpenAI.
UPB in da HIZZLE
Tempur Sealy reports Q1 adjusted EPS 50c, consensus 23c
Reports Q1 revenue $1.19B, consensus $1.09B. Company chairman and CEO Scott Thompson commented, "We are pleased to report solid first quarter sales, earnings and record operating cash flow against a global backdrop which appears to be at a historical nadir. The strong reception to our newly launched innovative products and our ongoing investment in compelling marketing to support the industry, combined with our broad-based omni-channel reach and our commitment to driving operational efficiencies, drove our industry outperformance in the first quarter. Although we look forward to the market's recovery, this recessionary environment provides opportunity to highlight the strength of our global business model and our leading competitive position. We continue to invest in our key initiatives and expect to emerge from the current downturn positioned well for long term success."
Perrigo backs FY24 adjusted EPS view $2.50-$2.65, consensus $2.35
Backs FY24 revenue view flat, consensus $4.66B. Backs FY24 adjusted tax rate 20.5%. Lockwood-Taylor continued, "We also delivered a good first quarter by advancing our operational priorities, including the successful launch of Opill(R), the first-ever over-the-counter oral contraceptive in the U.S., at more than 65,000 retail stores nationwide. Elsewhere, many of our key brands delivered healthy growth, leading to another quarter of strong topline growth in CSCI, while U.S. retailer de-stocking of store brand offerings across most categories impacted growth in CSCA. Quality improvement actions in infant formula are progressing well, and manufacturing volumes are expected to ramp in the second half of the year. The financial impact from infant formula in the quarter was expected and sizable, but I am proud that the team delivered meaningful year-over-year gross and operating margin expansion across the rest of the business. We remain focused on delivering on our operational priorities and outlook, while continuing to build One Perrigo."
Disney reports Q2 adjusted EPS $1.21, consensus $1.02
Reports Q2 revenue $22.1B, consensus $20.53B. "Our strong performance in Q2, with adjusted EPS(1) up 30% compared to the prior year, demonstrates we are delivering on our strategic priorities and building for the future," said Robert A. Iger, Chief Executive Officer, The Walt Disney Company. "Our results were driven in large part by our Experiences segment as well as our streaming business. Importantly, entertainment streaming was profitable for the quarter, and we remain on track to achieve profitability in our combined streaming businesses in Q4. Looking at our company as a whole, it's clear that the turnaround and growth initiatives we set in motion last year have continued to yield positive results. We have a number of highly anticipated theatrical releases arriving over the next few months; our television shows are resonating with audiences and critics alike; ESPN continues to break ratings records as we further its evolution into the preeminent digital sports platform; and we are turbocharging growth in our Experiences business with a number of near- and long-term strategic investments."
Palantir price target raised to $20 from $18 at Deutsche Bank
Deutsche Bank raised the firm's price target on Palantir to $20 from $18 and keeps a Sell rating on the shares. The company reported an "upbeat" Q1, led by sustained momentum in its U.S commercial business, where it is one of the earlier software companies to meaningfully monetize generative artificial intelligence, the analyst tells investors in a research note. However, the firm says Palantir's ability to drive stronger growth acceleration in 2024 is being constrained by its Government and International Commercial businesses "that aren't yet seeing similar AI tailwinds as US Commercial."
gooooooooood morning
Boeing tells Bloomberg employees violated company policy by skipping test
Boeing said it learned that several employees have been violating company policies by not performing a required test but recording the work as having been completed, the company said in an emailed statement to Bloomberg, citing Scott Stocker, 787 vice president and Boeing South Carolina site leader. "Fortunately, our engineering team has assessed that this misconduct did not create an immediate safety of flight issue. But it will impact our customers and factory teammates, because the test now needs to be conducted out of sequence on airplanes in the build process," Boeing is quoted as having said. Boeing said it has zero tolerance for not following processes designed to ensure quality and safety and is taking "swift and serious corrective action with multiple teammates," adding that the company learned of the issue after an employee saw something in a factory that he believed was not being done right, and spoke up about it.
Goldman says Gossamer's new deal validates attractive opportunity for seraltunib
Goldman Sachs notes that Gossamer Bio has announced that it has reached an agreement with Chiesi Farmaceutici to commercialize and further develop seralutinib, which in the firm's view provides external validation of a competitive, de-risked PAH asset that has been largely dismissed by the market. More specifically, the agreement calls for advancing the development of seralutinib in pulmonary hypertension associated with interstital lung disease, or PH-ILD, to co-commercialize seralutinib in PH-ILD and pulmonary arterial hypertension, or PAH, in the U.S., and to form a royalty agreement in an out-licensing royalty deal of seralutinib's ex-U.S. rights to Chiesi. The immediate development reimbursement payment of $160M improves Gossamer's capital position, in Goldman's view. The firm has a Buy rating on the shares with a price target of $8.
Goldman says Gossamer's new deal validates attractive opportunity for seraltunib
Goldman Sachs notes that Gossamer Bio has announced that it has reached an agreement with Chiesi Farmaceutici to commercialize and further develop seralutinib, which in the firm's view provides external validation of a competitive, de-risked PAH asset that has been largely dismissed by the market. More specifically, the agreement calls for advancing the development of seralutinib in pulmonary hypertension associated with interstital lung disease, or PH-ILD, to co-commercialize seralutinib in PH-ILD and pulmonary arterial hypertension, or PAH, in the U.S., and to form a royalty agreement in an out-licensing royalty deal of seralutinib's ex-U.S. rights to Chiesi. The immediate development reimbursement payment of $160M improves Gossamer's capital position, in Goldman's view. The firm has a Buy rating on the shares with a price target of $8.
$GME
GAMESTOP SHARES EXTEND DECLINES, LAST DOWN 15.3%
Elon Musk's no.2 at Tesla goes back to China as the CEO isolates himself at the top
electrek.co
NIO call volume above normal and directionally bullish
Bullish option flow detected in NIO with 66,308 calls trading, 4x expected, and implied vol increasing over 2 points to 81.70%. 5/10 weekly 6 calls and 5/10 weekly 6.5 calls are the most active options, with total volume in those strikes near 15,000 contracts. The Put/Call Ratio is 0.34. Earnings are expected on June 6th.
ADBE paying
Market Action: it is a quiet start to what should be a relatively quiet week of trading compared to the volatility seen over the last several weeks. Action has also been stifled today with UK and Japanese markets on holiday. Bonds have a decent bid after Chair Powell removed tail risk of a rate hike this year. The softer jobs and services ISM reports helped revive rate cut hopes with nearly 50 bps priced in, and possibly starting as soon as September. Concurrently, rate cuts in Europe are largely expected in June. Bonds could find a haven bid again as Israel reportedly prepares for an invasion of Rafah. There is a very light U.S. data calendar with just claims and consumer confidence of interest. There is a heavy Fedspeak slate but there is not much to be said currently on policy. Supply may be the biggest market mover this week with the $125 B Treasury refunding on tap. There are more earnings reports but most of the big names are out of the way. Treasuries are extending gains with yields about 2 bps lower, even ahead of supply. The 2-year is -1.5 bps at 4.801%, down -20 bps after testing 5% in late April. The wi 3-year is -1.7 bps richer at 4.625%, versus 4.83% from April 26. And the wi 10-year is -1 bp lower at 4.490%. The note recently tested 4.70%. Meanwhile, European rates are about -2.5 bps lower. Wall Street opened in the green with the Dow up 0.5%, teh S&P 500 0.4% higher, and the NASDAQ advancing 0.3%5%. European bourses are some 0.5% firmer. The DXY continues to sag and has fallen to 104.934 and has closed with a 104 handle since April 9.
Pre-market rant --->
PNC Financial, TCW announce partnership
The PNC Financial Services Group and the TCW Group, a global asset manager, announced they are partnering to deliver private credit solutions to middle market companies. The PNC and TCW partnership formalizes and expands more than 15 years of collaboration between PNC and TCW, combining both institutions' credit expertise: TCW's 23-year track record of successfully originating, underwriting and managing direct lending portfolios; and the strengths of PNC's national client relationships and its leading middle market lending franchise. The new joint strategy will focus primarily on directly originated, senior secured cash-flow and asset-based loans to both sponsored and non-sponsored middle market companies.
Disney price target raised to $130 from $125 at Deutsche Bank
Deutsche Bank raised the firm's price target on Disney to $130 from $125 and keeps a Buy rating on the shares. The firm increased operating income estimates to reflect Parks, Sport and Studio, partially offset by lowered direct-to-consumer numbers. While the stock doesn't offer tremendous upside unless there is further multiple expansion, Disney can maintain its current price-to-earnings multiple and carry it forward to 2025 estimates as the year progresses on the back of strong earnings growth, the analyst tells investors in a research note. Deutsche thinks the company "has regained its stride" and the risk of negative earnings revisions for the remainder of the year is relatively low, with positive revisions having a higher probability
Magna price target lowered to $57 from $60 at Raymond James
Raymond James lowered the firm's price target on Magna to $57 from $60 and keeps a Market Perform rating on the shares. Magna's Q1 results were generally below the firm's expectations after the company previously guided to Q1 representing the most challenging quarter of the year, the analyst tells investors in a research note.
$TSLA
? ELON MUSK CALLS ON WARREN BUFFET TO TAKE A STAKE IN TESLA
JUST IN 🚨: Robinhood $HOOD has received a Wells Notice from the SEC in regards to its crypto trading activities
The final frontier
After the space shuttle program was retired in 2011, NASA turned to private companies for space station deliveries. SpaceX began supply runs over a decade ago, before launching its first astronauts in 2020 and ending NASA's reliance on Russian spacecraft. It also beat Boeing (BA) in the race to space under NASA's Commercial Crew Program after the U.S. aerospace giant, whose resume goes back to the Apollo moon missions, ran into issues and delays during flight testing and manufacturing.
Out of this world: Commercial Crew was structured as a multi-tiered competition to get private sector companies to produce the most cost effective, innovative and safe way to get to the International Space Station. While SpaceX (SPACE) has already sent nine manned missions to the ISS with its Crew Dragon capsule, Boeing's Starliner is finally arriving to the launch pad. There's a lot on the line for the company, which has incurred $1.4B in accounting losses for the program, as well as recent reputation problems ranging from crashes of its MAX jets to a door plug that blew out mid-flight.
Starliner is set to blast off on Monday at 10:34 PM ET, with astronauts Barry Wilmore and Sunita Williams on board. The vehicle will launch from Cape Canaveral via an Atlas V rocket built by United Launch Alliance, a joint venture between Boeing and Lockheed Martin (LMT), and will take 26 hours to reach the space station. Starliner will return the pair to Earth about a week after docking with ISS, landing in the American Southwest with giant parachutes, in comparison to the iconic water splashdowns of SpaceX's Crew Dragon capsule.
Investing sphere: "With another $6.5B invested in Q1, there has now been $286B of equity investment into 1,779 unique space companies since 2015," Space Capital founder Chad Anderson wrote in the latest Space Investment Quarterly. "The total investment in Satellite infrastructure over the last decade overtook Launch for the first time in Q1 signaling that the balance has shifted from getting things into orbit, to developing capabilities now that we're there. Geospatial intelligence also overtook satellite communications for the first time, highlighting the growing demand for these orbital assets."
Woodstock of Capitalism
Warren Buffett wants his expected successor Greg Abel to take over stock investing decisions if he were to step down. "He understands businesses extremely well, and if you understand businesses, you understand common stocks," the Oracle of Omaha said at Berkshire Hathaway's (BRK.A) (BRK.B) annual shareholder meeting. The statement came after the conglomerate posted a 39% jump in its Q1 operating profit, along with a cash pile that hit a record $189B. Despite a major stake cut, Apple (AAPL) is expected to remain Berkshire's largest holding in 2024, though Elon Musk is trying to get Tesla (TSLA) in on the action. (49 comments)
Recovery plan
Trouble at Starbucks (SBUX) has prompted former Starbucks chief Howard Schultz to weigh in on the situation. "I've emphasized that the company's fix needs to begin at home: U.S. operations are the primary reason for the company's fall from grace," he wrote on LinkedIn, adding that the coffee giant needs to refocus on the customer experience after Q2 earnings "significantly" missed expectations. SBUX has declined 17% since then after slashing its guidance. SA analyst Luca Socci has sold his Starbucks position, but The Dividend Collectuh believes the bad news is a buying opportunity. (25 comments)
Earnings estimates
The Magnificent 7 contributes about one-fifth of the earnings growth to the S&P 500 (SPY) (IVV) (VOO) and analysts are ramping up expectations, according to Citi strategist Scott Chronert. Those stocks - Apple (AAPL), Amazon (AMZN), Alphabet (GOOG) (GOOGL), Meta (META), Microsoft (MSFT), Nvidia (NVDA), and Tesla (TSLA) - have seen Q1 earnings estimates rise more than 29%. (Nvidia has yet to report Q1). What about the other 493? Chronert says full-year earnings growth has become slightly less negative amid stabilization.
Today's Markets
In Asia, Japan closed. Hong Kong +0.6%. China +1.2%. India flat.
In Europe, at midday, London +0.5%. Paris +0.8%. Frankfurt +1%.
Futures at 7:00, Dow +0.3%. S&P +0.3%. Nasdaq +0.2%. Crude +1.1% to $78.98. Gold +0.8% at $2,327.60. Bitcoin +0.6% to $64,093.
Ten-year Treasury Yield -2 bps to 4.47%.
Today's Economic Calendar
12:50 PM Fed's Barkin Speech
1:00 PM Fed's Williams Speech
Companies reporting earnings today »
What else is happening...
Non-farm payrolls: Is worse than expected news good news?
Paramount (PARA) in formal negotiations with Apollo and SONY.
Tesla (TSLA) sets sights on Europe in latest self-driving push.
Mystik Dan: Kentucky Derby sets new wager record.
FTC's attack on high-profile executive rattles U.S. oil industry.
BTIG sees 'murky' road ahead for cannabis reclassification.
Trump Media (DJT) accounting firm charged with 'massive fraud.'
Major airlines agree on $8.5B Chicago O'Hare Airport upgrade.
ABC News president quits as Disney leadership reviews network.
Are AI stocks in a bubble? Here’s what Citadel's Ken Griffin thinks.
Ocean Power demonstrates advanced AI solutions in North Atlantic
Ocean Power Technologies announced it has completed multiple offshore demonstrations for potential customers of its Artificial Intelligence capable Maritime Domain Awareness Solution, Merrows. These demonstrations were conducted using the recently deployed Next Generation PowerBuoy. Philipp Stratmann, CEO and President of Ocean Power Technologies, expressed his enthusiasm about this milestone, stating, "There is no better tool to onboard new customers than to see our PowerBuoy based Maritime Domain Awareness Solution in its natural element, the open ocean. These field demonstrations truly highlight the advanced algorithms of the Merrows offering. They are helping us advance and accelerate our sales efforts and continue the revenue growth trajectory we have reported."
Bowlero reports Q3 adjusted EBITDA of $122.8 M vs. loss of $32.1M last year
Reports Q3 revenue $337.7M, consensus $341.51M. Reports Q3 SSS down 2.1%. Reports Adjusted EBITDA of $122.8 million versus prior year of $127.6 million and $67.4 million in 3QFY19..."Third quarter fiscal year 2024 started slowly due to weather. Post the first three weeks of January, we found a stable footing and increased investments to drive traffic. After the first three weeks of the quarter, we achieved a positive same-store-comp and double-digit total growth. Lucky Strike Miami opened in the quarter with exciting results, and we expect to have four more new builds opening in the next nine months with two in the Denver area and two in California. Summer Season Pass returned this year, and we expect that our continued investments in traffic will drive results throughout the spring and fall," said Thomas Shannon, Founder and Chief Executive Officer of Bowlero
Baidu price target lowered to $180 from $210 at Benchmark
Benchmark analyst Fawne Jiang lowered the firm's price target on Baidu to $180 from $210 and keeps a Buy rating on the shares ahead of the company's Q1 earnings report slated for May 16. Local ad checks suggested muted offline and SME ad spending in a low seasonal quarter, says the analyst, who has decided to take "a conservative approach" and revised down the firm's FY24 revenue and earnings estimates reflecting a lowered ad growth projection in light of a slow start.
gooooooooooooooooooood morning bobber
Followers
|
2447
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
363758
|
Created
|
02/25/08
|
Type
|
Free
|
Moderator jimmybob | |||
Assistants Mikey leemalone2k3 stutz7 uranium-pinto-beans retiredMM Nolerman |
FOSL | jimmybob | 02/14/2012 09:54:12 AM |
FOSL and SODA ~ WATCH!!! | jimmybob | 02/14/2012 09:50:52 AM |
uranium-pinto-beans | | Tuesday, February 14, 2012 12:43:05 PM | ||
Re: uranium-pinto-beans post# 82823 | | Post # of 87811 |
uranium-pinto-beans | | Tuesday, February 14, 2012 8:20:48 PM | ||
Re: uranium-pinto-beans post# 83085 | | Post # of 87811 |
jimmybob | | Friday, March 02, 2012 11:58:33 AM | ||
Re: jimmybob post# 87690 | | Post # of 87809 |
jimmybob | | Friday, March 02, 2012 12:10:44 PM | ||
Re: jimmybob post# 87692 | | Post # of 87809 |
jimmybob | | Monday, February 13, 2012 11:22:59 PM | ||
Re: jimmybob post# 80632 | | Post # of 87807 |
Posts Today
|
0
|
Posts (Total)
|
363758
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |